The main objective of this project is to assess the average cost of the treatment of bleeding postpartum with recombinant activated factor VII (NovoSeven®) and compare it to the reference strategy. Costs related to medicine NovoSeven® can generate surplus, but it also avoids in some cases very costly invasive procedures. It will be interesting to compare the average cost of the complete strategies supported.
Study Type
OBSERVATIONAL
Enrollment
84
direct medical cost
Time frame: day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.